In ovarian cancer, ARL6IP5 appeared to exert a tumor suppressive role, and as such, recombinant ARL6IP5 protein was demonstrated to sensitize the ovarian cancer cells to cisplatin [64]. This evidence concerns the gene ARL6IP5 and neoplasm.